Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Netarsudil Ophthalmic Solution 0.01%

Topical sterile ophthalmic solution

DRUG

Netarsudil Ophthalmic Solution 0.02%

Topical sterile ophthalmic solution

DRUG

Netarsudil Ophthalmic Solution 0.04%

Topical sterile ophthalmic solution

OTHER

Netarsudil Ophthalmic Solution Placebo

Topical sterile ophthalmic solution

Trial Locations (25)

Unknown

Nomura Eye Clinic, Ichinomiya-shi

Shisui ophthalmology clinic, Shisui

Nakamori Eye Clinic, Kitakyushu-shi

Southern TOHOKU Eye Clinic, Koriyama-shi

Kusatsu Eye Clinic, Hiroshima

Kanamori Eye Clinic, Akashi-shi

Sameshima Eye Clinic, Kagoshima

Asahigaoka Ophthalmology, Sendai

Sugao Eye Clinic, Osaka

Yubikai Kawaguchi Aozora Eye Clinic, Kawaguchi-shi

Hangai Eye Institute, Saitama-shi

Omiya Hamada Eye Clinic West Entrance Branch, Saitama-shi

Omiya Hamada Eye Clinic, Saitama-shi

Shibuya Ophthalmology Clinic, Saitama-shi

Yoshimura Eye & Internal Medical Clinic, Mishima

Medical Corporation Muramatsu Clinic Muramatsu Eye Clinic, Susono

Ueda Eye Clinic, Arakawa-ku

Ochanomizu Inoue Eye Clinic, Chiyoda-ku

Kiyosawa Eye Clinic, Koto-Ku

Tamagawa Eye Clinic, Ōta-ku

Seijo Clinic, Setagaya-Ku

Dogenzaka Kato Eye Clinic, Shibuya-ku

Wakabadai Eye Clinic, Shibuya-ku

Hashida Eye Clinic, Shinagawa-Ku

Watanabe Eye Clinic, Shinagawa-Ku

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT03844945 - Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan | Biotech Hunter | Biotech Hunter